Increasing Novel Drug Approval and Rising Prevalence of Chronic as well as acute illness are Anticipated to Fuel The Growth of the Global HERG Screening Market at a CAGR of 12.50% During the Forecast Period of 2023 to 2032

Pune, India, March 2024, MRFR Press Release/- Market Research Future has published a Cooked Research Report on the Global HERG Screening Market.

Market Highlights

Global HERG Screening Market is expected to have a market value of USD 2.6 Billion by 2032 at 12.50% CAGR during the assessment period of (2023-2032).

HERG screening has played an important role as a component of cardiac safety pharmacology for the past many years. Over the years, major market players in the HERG screening market are focusing on various growth strategies such as product launches, product advancements, and expansions to cater to the growing needs. For instance, Eurofins Scientific announced the acquisition of DiscoverX, a leader in drug discovery products and services across all stages of discovery from target identification and led discovery to preclinical and beyond.

Segment Analysis

Global HERG Screening Market is segmented into Type, i.e., gene KCNH2 and mutant KCNH2. KCNH2 gene that provides guidelines for producing potassium channels and held the largest market share in the hERG screening market. The global HERG screening market is segmented based on ion channel, further bifurcated into voltage-gated ion channel, ligand-gated ion channel, and others. Voltage-gated ion channel held the largest share in the HERG screening market, whereas ion-gated channel is the fastest-growing segment. The application segment is divided into antiarrhythmic drugs, antipsychotics, antibiotics, and others. The antiarrhythmic drug application segment is projected to account for a considerable market share.

Regional Analysis

The global HERG screening market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas held the largest share of 37.3% of the hERG screening market in 2019. This share can be attributed to technological development and the high prevalence of cardiac disease in the region.

The Europe HERG screening market has been segmented into Western Europe and Eastern Europe. The Western Europe HERG screening market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The major players of these countries are involved in new launches and acquisitions in the hERG screening market. The hERG screening market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The market growth in these countries is attributed to the large pool of patients suffering from cardiac disorders and the need for drug formulation and development to cure these disorders. The Middle East & Africa hERG screening market has been divided into the Middle East and Africa.

Explore In-depth Details: HERG Screening Market Research Report

Key Players

MRFR recognizes the following companies as the Key Players in the Global HERG Screening Market—Thermo Fisher Scientific, Eurofins Discover X Corporation, Charles River Laboratories, Merck KGaA, Metrion Biosciences Ltd, and Aurora Biomed, Inc.

Key Findings of the Study

• Global HERG Screening Market is estimated to reach USD 2.6 Billion by 2032 at a CAGR of 12.50% during the assessment period of 2023 to 2032.


• The Americas accounted for the largest share of the global HERG screening market due to the presence of prominent players in the US, high uptake rate, and product clearances from regulatory authorities.


• Based on type, the KCNH2 gene segment accounted for the largest market share of 15.09% in 2019.


• On the basis of ion channel, the voltage-gated ion channel segment is expected to be the fastest-growing segment during the forecast period with a CAGR of 15.05%.


• Based on application, the antiarrhythmic drug segment is expected to be the largest and fastest-growing segment at a CAGR of 15.5% during the forecast period.